Department of Pathology, Hospital Graz II, Location West, Göstinger Straße 22, 8020 Graz, Austria.
Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia.
Cells. 2021 Dec 30;11(1):117. doi: 10.3390/cells11010117.
Triple-negative breast cancer (TNBC) is a breast cancer (BC) subtype that accounts for approximately 15-20% of all BC cases. Cancer cell lines (CLs) provide an efficient way to model the disease. We have recently isolated a patient-derived triple-negative BC CL MFUM-BrTNBC-1 and performed a detailed morphological and molecular characterisation and a comprehensive comparison with three commercial BC CLs (MCF-7, MDA-MB-231, MDA-MB-453). Light and fluorescence microscopy were used for morphological studies; immunocytochemical staining for hormone receptor, p53 and Ki67 status; RNA sequencing, qRT-PCR and STR analysis for molecular characterisation; and biomedical image analysis for comparative phenotypical analysis. The patient tissue-derived MFUM-BrTNBC-1 maintained the primary triple-negative receptor status. STR analysis showed a stable and unique STR profile up to the 6th passage. MFUM-BrTNBC-1 expressed EMT transition markers and displayed changes in several cancer-related pathways (MAPK, Wnt and PI3K signalling; nucleotide excision repair; and SWI/SNF chromatin remodelling). Morphologically, MFUM-BrTNBC-1 differed from the commercial TNBC CL MDA-MB-231. The advantages of MFUM-BrTNBC-1 are its isolation from a primary tumour, rather than a metastatic site; good growth characteristics; phenotype identical to primary tissue; complete records of origin; a unique identifier; complete, unique STR profile; quantifiable morphological properties; and genetic stability up to (at least) the 6th passage.
三阴性乳腺癌（TNBC）是一种乳腺癌（BC）亚型，约占所有 BC 病例的 15-20%。癌细胞系（CLs）为疾病建模提供了一种有效的方法。我们最近分离了一个源自患者的三阴性 BC CL MFUM-BrTNBC-1，并对其进行了详细的形态学和分子特征描述，并与三个商业 BC CL（MCF-7、MDA-MB-231、MDA-MB-453）进行了全面比较。使用荧光显微镜进行形态学研究；免疫细胞化学染色用于检测激素受体、p53 和 Ki67 状态；RNA 测序、qRT-PCR 和 STR 分析用于分子特征描述；生物医学图像分析用于比较表型分析。源自患者组织的 MFUM-BrTNBC-1 保持了原发性三阴性受体状态。STR 分析显示，STR 谱在第 6 代时仍保持稳定和独特。MFUM-BrTNBC-1 表达 EMT 转化标志物，并显示出几种与癌症相关的途径（MAPK、Wnt 和 PI3K 信号传导；核苷酸切除修复；和 SWI/SNF 染色质重塑）的变化。形态上，MFUM-BrTNBC-1 与商业 TNBC CL MDA-MB-231 不同。MFUM-BrTNBC-1 的优势在于它是从原发性肿瘤而不是转移性部位分离出来的；具有良好的生长特性；与原发性组织的表型相同；完整的起源记录；独特的标识符；完整、独特的 STR 谱；可量化的形态学特性；以及遗传稳定性至少在第 6 代。
